Inuvo's IntentKey service allows advertisers to launch custom audiences on Safari and iPhone within 24 hours, maintaining ad performance despite Apple's iOS 27 privacy updates that limit tracking. Unlike traditional methods relying on personal data, IntentKey uses AI to understand user interests without cookies or personal profiles, preserving reach on Apple devices. This technology supports advertisers during the critical holiday season as more users adopt iOS 27. Advertisers can submit audience briefs to quickly activate campaigns across iPhone, iPad, and Mac devices.
Inuvo's IntentKey service is the subject, with Pluang's Technology-sector market data providing context. For readers following technology stocks, here is Pluang's market snapshot as of Nov 02, 2026 19:21 WIB: out of 150 priced US technology stocks, 96 rose and 40 fell today. Notable movers include NBIS at USD 158.00 with a 1-day change of +2.52%, Unity Software Inc (U) at USD 38.64 up +2.49%, and DigitalOcean Holdings Inc (DOCN) at USD 91.71 gaining +2.45%.
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
UroGen Pharma has dosed the first patient in a Phase 1 trial testing UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). The trial aims to evaluate the safety and tolerability of UGN-501 administered directly in...
